Barclays Issues Positive Forecast for bluebird bio (NASDAQ:BLUE) Stock Price

bluebird bio (NASDAQ:BLUE) had its target price hoisted by analysts at Barclays from $2.00 to $40.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s price target would suggest a potential upside of 379.62% from the stock’s previous close.

A number of other equities analysts have also recently weighed in on the stock. Royal Bank of Canada reissued a “sector perform” rating and issued a $80.00 price objective on shares of bluebird bio in a research report on Friday, November 15th. Cantor Fitzgerald reissued a “neutral” rating on shares of bluebird bio in a report on Monday, September 16th. Bank of America lowered bluebird bio from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $60.00 to $10.00 in a research note on Friday, November 15th. JPMorgan Chase & Co. lowered bluebird bio from a “neutral” rating to an “underweight” rating in a research report on Friday, November 15th. Finally, StockNews.com assumed coverage on shares of bluebird bio in a research report on Friday, December 20th. They set a “sell” rating for the company. Three analysts have rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, bluebird bio presently has an average rating of “Hold” and a consensus target price of $49.14.

bluebird bio Trading Up 6.1 %

NASDAQ BLUE opened at $8.34 on Tuesday. The stock has a market cap of $81.08 million, a P/E ratio of -4.46 and a beta of 0.72. The company’s fifty day simple moving average is $8.26 and its 200-day simple moving average is $13.03. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37. bluebird bio has a 52 week low of $5.80 and a 52 week high of $38.40.

Institutional Investors Weigh In On bluebird bio

Institutional investors and hedge funds have recently made changes to their positions in the company. Allegheny Financial Group LTD bought a new stake in bluebird bio during the second quarter valued at $25,000. Verition Fund Management LLC acquired a new stake in bluebird bio during the third quarter worth about $42,000. SG Americas Securities LLC lifted its holdings in bluebird bio by 152.4% in the third quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 74,185 shares during the last quarter. Captrust Financial Advisors lifted its holdings in bluebird bio by 48.2% in the third quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 77,293 shares during the last quarter. Finally, Barclays PLC boosted its stake in bluebird bio by 273.7% in the third quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after acquiring an additional 184,605 shares during the period. 87.43% of the stock is owned by institutional investors and hedge funds.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.